Advertisement
Table 3 Hazard ratios (HRs) and 95 % confidence intervals (CIs) for fractures and potential risk factors in the time-dependent model
| Variable | Crude HR (95 % CI) | p-value | Adjusted HR (95 % CI) | p-value | ||
|---|---|---|---|---|---|---|
| Age, years | 1.10 | (1.10-1.11) | <0.0001 | 1.09 | (1.08-1.10) | <0.0001 |
| Monthly income, NTD | ||||||
| <= 15000 | 4.85 | (3.98-5.91) | <0.0001 | 1.34 | (1.08-1.66) | 0.009 |
| 15001-20000 | 2.25 | (1.86-2.71) | <0.0001 | 1.51 | (1.25-1.82) | <0.0001 |
| >20000 | 1.00 | Ref. | 1.00 | Ref. | ||
| Comorbidity (yes vs. no) | ||||||
| Hypertension | 4.48 | (3.94-5.09) | <0.0001 | 1.27 | (1.09-1.48) | 0.002 |
| Hyperlipidemia | 2.19 | (1.92-2.50) | <0.0001 | 0.83 | (0.72-0.96) | 0.01 |
| Diabetes | 3.65 | (3.18-4.19) | <0.0001 | 1.59 | (1.37-1.85) | <0.0001 |
| PAD | 2.74 | (2.00-3.74) | <0.0001 | 0.99 | (0.72-1.36) | 0.96 |
| Stroke | 5.40 | (4.27-6.83) | <0.0001 | 1.38 | (1.08-1.76) | 0.01 |
| Osteoporosis | 3.11 | (2.70-3.58) | <0.0001 | 1.38 | (1.19-1.59) | <0.0001 |
| Aromatase inhibitor use before the end point | 1.18 | (1.00-1.40) | 0.049 | 0.80 | (0.68-0.95) | 0.01 |
